AbbVie/Shire Merger To Create Rare Disease Business Unit Headed By Ornskov
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire CEO Flemming Ornskov will stay on as $54.7 billion tax-reducing deal moves forward before any potential legislation could dilute its impact.